Original news and analysis on international IP policy
A research group announced in March that it has designed the first minimal synthetic bacterial cell. Rapid advances in science seem to be leaving the international normative process lagging behind. Current international instruments are seeking to understand how this new technology will impact their regulatory efforts, while civil society raises high concerns.
Speakers from Asian civil society provided recommendations to the public hearing of the United Nations Secretary General’s High-Level Panel on Access to Medicines held yesterday. They underlined the unaffordability of medicines in their countries, the inefficiency of current mechanisms such as voluntary licensing, and the pressure applied by pharmaceutical companies and the United States and Europe to prevent the use of compulsory licences. One speaker warned against the expert advice given by the World Intellectual Property Organization to least-developed countries, while others pointed to stringent intellectual property measures in free-trade agreements.
Two key senators today released dozens of comments they received in response to their report on the medicine Sovaldi (and its follow-on Harvoni), whose extreme high prices sparked a debate over pharmaceutical pricing that has created momentum for policy changes.
An initiative of the United Nations secretary general yesterday gathered what could be described as an assembly of many of the world’s best thinkers and practitioners on public health and intellectual property rights. Industry, activists, academics, international organisations, and possibly some governments poured out their views for nearly seven hours – at times coming to tears and tension – shepherded by an astute moderator, as they responded to the call to take a longstanding debate on medicines access and high prices to a breakthrough.
Today, Médecins Sans Frontières (MSF, Doctors Without Borders) filed a patent opposition against Pfizer’s vaccine for pneumonia in India.
The United States National Institutes of Health’s decision to consider granting an exclusive licence on patents for a newly government-developed vaccine to Sanofi has prompted a strong reaction from civil society warning against potential high prices and requesting transparency in the process.
The United Nations Secretary General’s High-Level Panel on Access to Medicines is holding a global dialogue this month, attended by governments, civil society, industry and academia, to discuss potential solutions to promote innovation and at the same time increase access to medicines. The first public dialogue session is this week, on 10 March in London.
The United Nations High Commissioner for Human Rights, Zeid Ra'ad Al Hussein, today issued a statement urged United States law enforcement authorities to exercise caution in their legal fight against Apple computer company, saying it could have "extremely damaging implications for the human rights of many millions of people, including their physical and financial security."
Whether laws enforcing transparency on costs would help curb extortionate drug prices in today’s world is hardly predictable now that pharma companies and their allies are lobbying governments to scupper any rules that would require them to disclose the real R&D costs and profits of their medicines and the rationale for charging what they do, writes Daniele Dionisio.
The World Intellectual Property Organization, a specialized agency of the United Nations, was unique among Geneva-based UN agencies for offering views at both recent meetings of the UN High-Level Panel on Access to Medicines held in Geneva and New York this month. Now WIPO has come under criticism from public health advocates for the views it gave.
Today, United States President Barack Obama sent two signed multilateral copyright treaties negotiated at the World Intellectual Property Organization to the US Senate for ratification.
NEW YORK -- It came as a surprise to some when the United Nations Secretary General’s office announced in November the setting up of a high level panel to urgently address access to medicines and other health technologies. After all, UN agencies in Geneva, most notably the World Health Organization, have been working on these issues for years. Yesterday at the UN in New York, an event was held to explain some of the vision and urgency behind the setting up of the panel, which includes an expert committee of representatives of some 10 international organisations and others. It also includes an open online call for contributed ideas until 18 February, and two public hearings.